R1 RCM — Corporate Update (June 2022)
13 slides from R1 RCM's corporate update, Jun 27, 2022
Slide 1: Guidance Update Call
Guidance Update Call NEED NEW IMAGE THAT WE SENT June 27, 2022 Exhibit 99.1
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation includes information that may constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking
Slide 3: Presenters
3 Lee Rivas President Presenters Joseph Flanagan Chief Executive Officer Rachel Wilson Chief Financial Officer & Treasurer
Slide 4: Transaction Recap and Cloudmed Update
4 Transaction Recap and Cloudmed Update
Slide 5: Strategic and Financial Highlights
5 Leading data and analytics-driven revenue intelligence platform Leading end-to-end technology- driven platform to manage healthcare provider revenue Powerful Combination of Market-leading Platforms ▪ Accelerates growth by unlocking full market potential ▪ Extends leadership in revenue cycle automa
Slide 6: Transaction Close Summary
6 Management and Board ▪ CEO: Joe Flanagan ▪ President: Lee Rivas ▪ Three new directors joined R1’s Board: ▪ Kyle Armbrester, CEO of Signify Health ▪ Jeremy Delinsky, COO of Devoted Health ▪ Matthew Holt, MD and President, Private Equity of New Mountain Capital Timing and Share Issuance ▪ Transactio
Slide 7: President's Update
7 Integration Execution on Track ▪ Sales teams integrated; significant opportunity across combined customer base ▪ Combined technology architecture creates leading RCM platform ▪ Cost synergy plans developed and realization is on track Cloudmed Executing Ahead of Plan ▪ Cross-sell execution combined
Slide 8: Guidance Update
8 Guidance Update
Slide 9: 2022 Guidance Bridge
9 2022 Guidance Bridge Note: Adjusted EBITDA is a non-GAAP measure; please refer to the Appendix for more information and a reconciliation of historical non-GAAP financial measures. $1,660 - $1,700 $1,850 - $1,870 $470 - $480 ($ in millions) $385 - $405 ~$70 ~$240 ~$9 ~$13 ~$105 Standalone Guidance
Slide 10: Expected 2022 Quarterly Adjusted EBITDA Progression
10 Expected 2022 Quarterly Adjusted EBITDA Progression Note: Adjusted EBITDA is a non-GAAP measure; please refer to the Appendix for more information and a reconciliation of historical non-GAAP financial measures. ▪ Q2 expected Adjusted EBITDA of $85-87 million reflects contribution from Cloudmed an
Slide 11: Financial Outlook Post-2022
11 Financial Outlook Post-2022 End-to-End NPR Growth 12-14%1 Modular Revenue Growth ~20% Adjusted EBITDA Growth 17%+ Medium-Term Adj. EBITDA Margin Target2 30%+ Long-Term Adj. EBITDA Margin Target 35%+ Note 1: Assumes $10B NPR contract is split between 2022 and 2023. Note 2: Medium-term is defined a
Slide 12: Appendix
endix p Ap ©) al
Slide 13: Use of Non-GAAP Financial Measures
13 Use of Non-GAAP Financial Measures ▪ In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial performance